Arca
Skip to content
Tools
Tools

MST1R: Macrophage-stimulating protein receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 4

Who Is On It, and How Far Along

Every drug ChEMBL records acting on MST1R, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody

Approved1

  • Crizotinib

Phase 30

    Phase 22

    • Glesatinib
    • Narnatumab

    Phase 11

    • MK-8033

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Mirati Therapeutics Inc.125%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule375%
    • Antibody125%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Macrophage-stimulating protein receptor inhibitor.
    CrizotinibApprovedPfizerSmall moleculeInhibitor—39—
    GlesatinibPhase 2Mirati Therapeutics Inc.Small moleculeInhibitor—0—
    NarnatumabPhase 2Eli LillyAntibodyInhibitor—0—
    MK-8033Phase 1Merck & Co. (MSD)Small moleculeInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid TumorsCrizotinibNot applicableActive, not recruitingNational Cancer Center, Korea2026-10-23
    A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerCrizotinibPhase 3Not yet recruitingGuangzhou JOYO Pharma Co., Ltd2026-09-11
    Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaCrizotinibPhase 3RecruitingIDEAYA Biosciences2026-09-04
    Molecularly Tailored Therapy in Advanced Pancreatic CancerCrizotinibPhase 2Not yet recruitingHerlev Hospital2026-09-03
    Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)CrizotinibPhase 1 / Phase 2Not yet recruitingChina Medical University Hospital2026-05-01
    A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionCrizotinibPhase 1Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.2026-04-20
    Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaCrizotinib—RecruitingFirst People's Hospital of Hangzhou2025-10-03
    Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCCrizotinib—Not yet recruitingNational Cancer Center, China2024-11-19

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Nasopharyngeal neoplasm
    0.62
    Non-small cell lung carcinoma
    0.59
    Neoplasm
    0.41
    Cancer
    0.32
    Plasma cell myeloma
    0.29
    Non-small cell squamous lung carcinoma
    0.28
    Inflammatory myofibroblastic tumor
    0.20
    Abnormality of the skeletal system
    0.12

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2689, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q04912, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.